电子烟或雾化产品使用相关肺损伤(EVALI):病例系列与诊断流程
该病例系列报告了2019年6月6日至9月15日罗切斯特大学医学中心收治的12例疑似EVALI患者,定义是就诊前30天内使用电子烟或其他雾化装置且胸部影像(CT或X线)显示双肺含气腔隙混浊。最常见症状为呼吸困难、发热和呕吐(10例,83%),咳嗽9例(75%);11例(92%)报告使用含四氢大麻酚油的电子烟弹。8例(67%)因低氧性呼吸衰竭入住ICU,无死亡,中位住院7天(IQR 7–8)。完成随访的6例(50%)胸部CT异常均消退且肺功能正常。作者与纽约州卫生局合作制定了首个EVALI临床实践流程,强调在作出推定诊断前排除感染及其他心肺疾病。
要点
- 疑似EVALI定义:就诊前30天内使用电子烟或其他雾化装置,且胸部影像(CT或X线)显示双肺含气腔隙混浊。
- 12例疑似EVALI中8例(67%)因低氧性呼吸衰竭入住ICU,无死亡,中位住院7天(IQR 7–8)。
- 11例(92%)报告使用含四氢大麻酚油的电子烟弹,提示THC产品是 nationwide 调查重点。
- 完成随访的6例(50%)胸部CT异常均消退且肺功能正常,多数在起病1–2周内改善。
- 临床流程强调作出EVALI推定诊断前必须排除感染及其他心肺疾病。
适用人群与场景
- 就诊前30天内使用电子烟或其他雾化装置、胸部影像(CT或X线)显示双肺含气腔隙混浊的住院患者。
- 本研究为罗切斯特大学医学中心收治的疑似EVALI患者,年龄及基础疾病等纳入排除细节原文未报告。
诊断标准与关键阈值
- 病例定义:就诊前30天内使用电子烟或其他雾化装置,且胸部影像(CT或X线)显示双肺含气腔隙混浊。
- 临床流程强调在作出EVALI推定诊断前排除感染及其他心肺疾病。
处置流程与药物剂量
- 停用雾化产品并给予支持治疗。
- 必要时给予全身糖皮质激素(原文未写明药名、剂量、途径及疗程)。
- 8例(67%)因低氧性呼吸衰竭入住ICU接受管理。
红旗征与不能漏的情况
- 低氧性呼吸衰竭需入住ICU。
- 胸部影像双肺含气腔隙混浊。
研究设计与关键结果
- 单中心病例系列,纳入2019年6月6日至9月15日罗切斯特大学医学中心12例疑似EVALI患者。
- 10例(83%)有呼吸困难、发热和呕吐,9例(75%)有咳嗽;11例(92%)报告使用含四氢大麻酚油的电子烟弹。
- 8例(67%)因低氧性呼吸衰竭入住ICU,无死亡;中位住院时间7天(IQR 7–8)。
- 完成随访的6例(50%)胸部CT异常均消退且肺功能正常。
证据类型、等级与局限
- 证据类型:病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对使用电子烟或雾化装置后出现呼吸困难、咳嗽、低氧及双肺含气腔隙混浊的患者,应怀疑EVALI并询问THC产品使用史。
- 作出EVALI推定诊断前需排除感染及其他心肺疾病。
- 处理包括停用雾化产品、支持治疗,必要时使用全身糖皮质激素;原文未给出具体药物剂量方案。
指南或共识出处
- 原文未引用指南或共识。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Since June, 2019, more than 1000 new cases of e-cigarette, or vaping, product use associated lung injury (EVALI) have been reported in the USA. Patients presented with dyspnoea, cough, and were found to be hypoxaemic with bilateral airspace opacities on chest imaging. Most patients required management in the intensive care unit and steroid therapy. All patients recovered with cessation of vaping, supportive care, and steroid therapy and remained symptom free at follow up. E-cigarette use continues to rapidly escalate in the USA, particularly among youth.
METHODS: Cases were defined as patients admitted to the University of Rochester Medical Center (Rochester, NY, USA) who had used e-cigarettes or another vaping device in the 30 days before presentation, and who had bilateral airspace opacification on chest imaging (CT or x-ray). Case details were obtained via medical record review and patient interviews over the past 3 months including symptomatology, physical exam data, imaging studies, laboratory data, vaping history, and subsequent outpatient follow-up data. In collaboration with the New York State Department of Health, our hospital developed a novel clinical practice algorithm based on statewide physician feedback along with input from experts in environmental health, medical toxicology, infectious disease, epidemiology, and chronic disease prevention.
FINDINGS: We report 12 cases treated for suspected EVALI at our medical centre between June 6, 2019, and Sept 15, 2019. Ten (83%) patients had dyspnoea, fever, and emesis and nine (75%) had cough. 11 (92%) patients reported the use of e-cigarette cartridges containing tetrahydrocannabinol oil. Although eight (67%) patients required admission to the intensive care unit for hypoxaemic respiratory failure, no deaths occurred. The median hospitalisation duration was 7 days (IQR 7-8). All patients completing follow up (6 [50%]) had resolution of previous chest CT findings and normal spirometry. The clinical algorithm focuses on the key signs and symptoms of EVALI and the importance of ruling out infection and other cardiopulmonary conditions before making a presumptive diagnosis of EVALI.
INTERPRETATION: Patients with suspected EVALI in our cohort had life-threatening hypoxaemia, with 67% requiring management in the intensive care unit. Despite the severity of presentation, similar to previous reports of patients with EVALI, most patients improved within 1-2 weeks of initial presentation after vaping cessation and administration of systemic corticosteroids when needed. Almost all (92%) patients with suspected EVALI reported vaping a THC product, making THC containing e-liquids or oils a key focus on the ongoing nationwide investigations into the cause of EVALI. Additional research is required to understand the potential toxins, underlying pathophysiological mechanisms, and identification of susceptible individuals at higher risk for hospitalisation due to EVALI. To our knowledge we present the first clinical practice algorithm for the evaluation and management of EVALI, which will be useful for both acute management and improved accurate reporting of this life-threatening respiratory illness.
参考来源
- Kalininskiy A, Bach CT, Nacca NE, et al. E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. Lancet Respir Med. 2019. PMID: 31711871. doi:10.1016/S2213-2600(19)30415-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。